Alnylam stock trading halted today; fda advisory committee to review supplemental new drug application for patisiran for the treatment of the cardiomyopathy of attr amyloidosis

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that nasdaq has halted trading of the company's common stock. the u.s. food and drug administration's (fda) cardiovascular and renal drugs advisory committee is meeting today to review the supplemental new drug application for patisiran, an investigational rnai therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (attr) a.
ALNY Ratings Summary
ALNY Quant Ranking